Rationale and design of the multicentre randomized trial investigating the efficacy and safety of pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep study)
- 18 January 2010
- journal article
- research article
- Published by Wiley in European Journal of Heart Failure
- Vol. 12 (2), 186-192
- https://doi.org/10.1093/eurjhf/hfp189
Abstract
Advanced chronic heart failure (CHF) is a clinical syndrome with high morbidity and mortality that often requires inotropic support for the alleviation of symptoms and congestion. There are no definite evidence-based data on the safety and efficacy of intermittent infusions of inotropic agents in this severe clinical condition. The purpose of the LevoRep study is to clarify whether pulsed infusions of the new inotropic agent levosimendan administered in an outpatient setting can safely improve exercise capacity, quality-of-life (QoL), and outcome in advanced CHF patients. The LevoRep study is a prospective, randomized, double-blind, placebo-controlled, two-armed, parallel-group, multicentre trial. The study is designed to investigate the effects of pulsed infusions of levosimendan (6 h administration at 0.2 microg/kg/min every 2 weeks) on the composite endpoint (primary endpoint) comprising changes in functional capacity and QoL (20% or greater improvement in the 6 min walk test and 15% or higher score on the Kansas City Cardiomyopathy Questionnaire) at the end of the 24 week study period. In addition, short-term (8 weeks from randomization) and long-term (24 weeks from randomization) event-free survival (secondary endpoint) will be assessed. The LevoRep study aims to include 120 outpatients with advanced CHF. LevoRep is the first prospective randomized trial to assess the effects of pulsed infusions of an inotrope on hard endpoints as well as on the safety in patients with advanced CHF on an outpatient basis. The results are expected to promote the development of evidence-based recommendations for the ambulatory management of patients with end-stage heart failure.This publication has 34 references indexed in Scilit:
- Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot StudyThe Journal of Clinical Pharmacology, 2009
- Novel biologic mechanisms of levosimendan and its effect on the failing heartExpert Opinion on Investigational Drugs, 2008
- Levosimendan: current status and future prospectsCurrent Opinion in Anaesthesiology, 2008
- Effects of Levosimendan on Quality of Life and Emotional Stress in Advanced Heart Failure PatientsCardiovascular Drugs and Therapy, 2007
- Effects of serial levosimendan infusions on left ventricular performance and plasma biomarkers of myocardial injury and neurohormonal and immune activation in patients with advanced heart failureHeart, 2006
- European Experience on the Practical Use of Levosimendan in Patients with Acute Heart Failure SyndromesThe American Journal of Cardiology, 2005
- Efficacy and safety of intermittent, long-term, concomitant dobutamine and levosimendan infusions in severe heart failure refractory to dobutamine aloneThe American Journal of Cardiology, 2005
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failureAmerican Heart Journal, 1986
- Intermittent, continuous outpatient dobutamine infusion in the management of congestive heart failureThe American Journal of Cardiology, 1983